Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI, a US-China Biopharma, Completes $38 Million Private Placement

publication date: Jul 22, 2020

CASI Pharma, a US biopharma developing products for China, raised $38 million in a private placement of 20 million shares of its common stock. The company intends to use the proceeds to advance its product portfolio, acquire rights to new products and general/administrative expenses. CASI in-licenses products for China. One year ago, it launched its first product, Evomela® (Melphalan for Injection), in China, a conditioning treatment used prior to stem cell transplantation for multiple myeloma. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital